178 related articles for article (PubMed ID: 35577644)
1. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E; Hussain SA; Porta N; Lewis R; Crundwell M; Jenkins P; Rawlings C; Tremlett J; Sreenivasan T; Wallace J; Syndikus I; Sheehan D; Lydon A; Huddart R; James N;
Eur Urol; 2022 Sep; 82(3):273-279. PubMed ID: 35577644
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
James ND; Hussain SA; Hall E; Jenkins P; Tremlett J; Rawlings C; Crundwell M; Sizer B; Sreenivasan T; Hendron C; Lewis R; Waters R; Huddart RA;
N Engl J Med; 2012 Apr; 366(16):1477-88. PubMed ID: 22512481
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart RA; Hall E; Lewis R; Porta N; Crundwell M; Jenkins PJ; Rawlings C; Tremlett J; Campani L; Hendron C; Hussain SA; James ND;
Eur Urol; 2020 Feb; 77(2):260-268. PubMed ID: 31843338
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury A; Porta N; Hall E; Song YP; Owen R; MacKay R; West CML; Lewis R; Hussain SA; James ND; Huddart R; Hoskin P;
Lancet Oncol; 2021 Feb; 22(2):246-255. PubMed ID: 33539743
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
Hussain SA; Porta N; Hall E; Salawu A; Lewis R; Sreenivasan T; Wallace J; Crundwell M; Jenkins P; Tremlett J; Huddart R; James ND;
Eur Urol; 2021 Feb; 79(2):307-315. PubMed ID: 33293079
[TBL] [Abstract][Full Text] [Related]
6. The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Choudhury A; West CM; Porta N; Hall E; Denley H; Hendron C; Lewis R; Hussain SA; Huddart R; James N
Br J Cancer; 2017 Feb; 116(5):649-657. PubMed ID: 28125821
[TBL] [Abstract][Full Text] [Related]
7. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Huddart RA; Hall E; Hussain SA; Jenkins P; Rawlings C; Tremlett J; Crundwell M; Adab FA; Sheehan D; Syndikus I; Hendron C; Lewis R; Waters R; James ND
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):261-9. PubMed ID: 23958147
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
de Ruiter BM; van Hattum JW; Lipman D; de Reijke TM; van Moorselaar RJA; van Gennep EJ; Maartje Piet AH; Donker M; van der Hulle T; Voortman J; Oddens JR; Hulshof MCCM; Bins AD
Eur Urol; 2022 Nov; 82(5):518-526. PubMed ID: 35933242
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
10. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Hussain SA; Stocken DD; Peake DR; Glaholm JG; Zarkar A; Wallace DM; James ND
Br J Cancer; 2004 Jun; 90(11):2106-11. PubMed ID: 15150587
[TBL] [Abstract][Full Text] [Related]
12. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Tan WS; Prendergast A; Ackerman C; Yogeswaran Y; Cresswell J; Mariappan P; Phull J; Hunter-Campbell P; Lazarowicz H; Mishra V; Rane A; Davies M; Warburton H; Cooke P; Mostafid H; Wilby D; Mills R; Issa R; Kelly JD
Eur Urol; 2023 Jun; 83(6):497-504. PubMed ID: 35999119
[TBL] [Abstract][Full Text] [Related]
15. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K
Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis].
Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240
[No Abstract] [Full Text] [Related]
19. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
Kumar A; Cherry DR; Courtney PT; Nalawade V; Kotha N; Riviere PJ; Efstathiou J; McKay RR; Karim Kader A; Rose BS; Stewart TF
Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
[TBL] [Abstract][Full Text] [Related]
20. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS; van de Kamp MW; Schuring N; Mertens LS; Noordzij A; Pos F; van Rhijn BWG; van der Heijden MS; Schaake EE
Radiother Oncol; 2020 Sep; 150():275-280. PubMed ID: 32768507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
